Form 4: Oncocyte CFO Andrea James Receives Stock Options and Restricted Stock Units

Andrea James, CFO of Oncocyte Corp, was granted stock options and restricted stock units on June 20, 2024, subject to shareholder approval and certain vesting conditions.

Summary

• On June 20, 2024, Oncocyte Corp granted Andrea James, the Chief Financial Officer, stock options and restricted stock units (RSUs).
• The grant includes options to purchase 200,000 shares of common stock at an exercise price of $2.87.
• Additionally, 100,000 RSUs were granted, subject to both time and performance-based vesting conditions.
• The grants are contingent upon shareholder approval of an increase in the number of shares available under the Oncocyte 2018 Equity Incentive Plan.
• The stock options vest over time, with 25% vesting one year after the grant date and the remaining 75% vesting in monthly installments over the following three years.
• The RSUs vest based on performance, with 50% vesting upon Oncocyte achieving an aggregate market value of $75 million and no longer being subject to the Baby Shelf Rules of Form S-3.
• The remaining 50% of the RSUs vest upon Oncocyte achieving a market capitalization of $200 million, based on the 30-day volume-weighted average price.
• Any RSUs that do not vest by December 31, 2026, will be forfeited.

Sentiment

Score: 7

Explanation: The document reflects a positive development for the CFO and aligns her interests with the company's success, but it is also contingent on certain approvals and performance targets.

Positives

• The grants of stock options and RSUs align the CFO's interests with those of the shareholders.
• The performance-based vesting of the RSUs incentivizes the CFO to drive company growth and increase shareholder value.
• The vesting schedule encourages long-term commitment from the CFO.

Negatives

• The grants are contingent on shareholder approval, which introduces some uncertainty.
• The performance targets for the RSUs may be challenging to achieve, and any RSUs that do not vest by December 31, 2026, will be forfeited.

Risks

• Failure to obtain shareholder approval for the increase in shares available under the equity incentive plan would impact the grant.
• The company may not achieve the market value and market capitalization targets required for the RSUs to vest.
• Changes in market conditions or company performance could affect the vesting of the stock options and RSUs.

Future Outlook

The document outlines future vesting events contingent on shareholder approval, continued employment, and the achievement of specific market value and market capitalization targets.

Industry Context

Equity grants are a common practice in the biotech industry to attract and retain key executives, aligning their interests with those of shareholders and incentivizing company growth.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for CFOs in publicly traded companies, particularly in the biotechnology sector.
• Vesting schedules and performance-based conditions are also common to ensure long-term commitment and alignment with company goals.
• Comparable companies like Exact Sciences or Guardant Health also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with increasing shareholder value.
• Employees may be motivated by the potential for company growth and the achievement of performance targets.
• The grants have no immediate impact on customers, suppliers, or creditors.

Next Steps

• Shareholder approval of the increase in shares available under the Oncocyte 2018 Equity Incentive Plan.
• Filing of an additional Form 4 after shareholder approval.
• Monitoring of Oncocyte's market value and market capitalization to track progress towards RSU vesting.

Key Dates